Fig. 7
From: TAZ couples Hippo/Wnt signalling and insulin sensitivity through Irs1 expression
Statin treatment inhibits insulin signalling via TAZ degradation. a Insulin was intraperitoneally injected into vehicle- or simvastatin-administered mice. After 15 min, muscle lysates were analysed by immunoblotting. α-Tubulin was used as a loading control. Simvastatin or vehicle was administered to 6-week-old mice for 3 weeks. b Three independent experiments performed as described in a were assessed, and the ratios of IRS1 and TAZ to α-tubulin were analysed; in addition, the ratios of phosphorylated to total AKT, AS160, and ribosomal protein S6 kinase were determined (n = 3). c C2C12 cells were transduced with control, wild-type TAZ, or proteolytic degradation-resistant TAZ (TAZ4SA; TAZ S58, 62, 306, 309A) retroviral vectors to establish stable cell lines. Then, 10 μM simvastatin or DMSO was added to cells for 48 h, and IRS1 and TAZ level in harvested cells was analysed by immunoblotting. d Irs1 expression in the cells described in c was analysed by qRT-PCR and normalised to Gapdh expression (n = 3). e Glucose uptake was analysed in control, wild-type TAZ, and TAZ4SA-overexpressing C2C12 myotubes (n = 3). Data are presented as mean ± SD. Statistical analysis was performed using a Student’s t-test. ns not significant; *p < 0.05; **p < 0.01; ***p < 0.005
